Samsung Biologics Signs $2.2B CDMO Deal with Major US Pharma Company
Samsung Biologics' mega-deal confirms South Korea's emergence as the world's premier biologics CDMO hub, rivaling traditional manufacturing centers in the US and Europe.
Samsung Biologics secured its largest ever $2.2 billion multi-year CDMO contract with a major US pharmaceutical company for biologics manufacturing at its Songdo campus.
Samsung Biologics has signed a $2.2 billion contract development and manufacturing organization (CDMO) deal with an undisclosed major US pharmaceutical company. The multi-year agreement covers biologics manufacturing at Samsung's Songdo campus, which will have total capacity of 784,000 liters upon completion of Plant 4. This is the largest single CDMO contract in the company's history.
Samsung Biologics' mega-deal confirms South Korea's emergence as the world's premier biologics CDMO hub, rivaling traditional manufacturing centers in the US and Europe.
Where this signal fits in the broader landscape.
https://koreajoongangdaily.joins.com/news/2025-05-26/business/industry/Samsung-Biologics-manufacturing-deals-exceed-22-billion-this-year/2315474
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
ログイン